{"id":701823,"date":"2022-10-27T08:20:33","date_gmt":"2022-10-27T12:20:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/"},"modified":"2022-10-27T08:20:33","modified_gmt":"2022-10-27T12:20:33","slug":"rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/","title":{"rendered":"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEWARK, Calif., Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; Rain Therapeutics Inc. (NasdaqGS: RAIN), (\u201cRain\u201d), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company\u2019s business and financial results.<\/p>\n<p align=\"left\">\n        <strong>Conference Call and Webcast Details: <\/strong><br \/>\n        <br \/>Date: November 10, 2022<br \/>Time: 2:00 PT (5:00 pm ET)<br \/>Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) \/ 1 (201) 389-0920 (International)<\/p>\n<p align=\"left\">Conference ID: 13733093<\/p>\n<p align=\"left\">Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b1itp4h7KwAXSeoWR8GuR9RvGugArJ_tAbotOV8pjLGjvfBWG10hGehbgfODXc8RXMgI7Ny_1mHVRjZbxZ-F81J3-go4skeqchC-32ikBxaRje8Q2J9a-NvBfCxiGWLWxAQWxm5alWkIIdNwWjG1pg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/2vzj7av9<\/a><\/p>\n<p align=\"left\">Replay of the call will be available by visiting the &#8220;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UEYsglU3IcJEhbBc_n1hsBCRRoAU-LqjhlfLPqE2ZuSLJZnCuFMK8QGa6LyazzJCOXKNMCf8odvWn73lE06ezA==\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a>&#8221; section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.<\/p>\n<p align=\"left\">\n        <strong>About Rain Therapeutics Inc.<\/strong><br \/>\n        <br \/>Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors\u2019 underlying genetics rather than histology. Rain\u2019s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.<\/p>\n<p align=\"left\">\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Dan Ferry<br \/>LifeSci Advisors<br \/>+1.617.430.7576<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Shb9QzRnijXG0u7TDR-uifi8X1ouQdj9vkMt-533W2QjhE1xwheLldgnazO1yNlwfxhT3yh0Ghuj2fg_pPs6uyhQj-nJ3U5i1dAMguo0o3SsAz8xF4JADdTW0GjV4zYW\" rel=\"nofollow noopener\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Jordyn Temperato<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c4RQ8klZMSjNTvjkhSP6lYKoB1HD1rVyHFL69c-L-0lFoSmEmco2njElqFkcj8T_2kAMPdG--XdPT6-bC2tsKMB1u2pocoPHeh8-yClPu17WqvTCsLSxFDwUapHnLwu4\" rel=\"nofollow noopener\" target=\"_blank\">jtemperato@lifescicomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWY4ZmM5ZDUtN2U4MS00ZDNmLWEyNTMtMzk0YWFiOTI0Yzg3LTEyMTc3NTI=\/tiny\/Rain-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Rain Therapeutics Inc. (NasdaqGS: RAIN), (\u201cRain\u201d), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company\u2019s business and financial results. Conference Call and Webcast Details: Date: November 10, 2022Time: 2:00 PT (5:00 pm ET)Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) \/ 1 (201) 389-0920 (International) Conference ID: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701823","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Rain Therapeutics Inc. (NasdaqGS: RAIN), (\u201cRain\u201d), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company\u2019s business and financial results. Conference Call and Webcast Details: Date: November 10, 2022Time: 2:00 PT (5:00 pm ET)Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) \/ 1 (201) 389-0920 (International) Conference ID: &hellip; Continue reading &quot;Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:20:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022\",\"datePublished\":\"2022-10-27T12:20:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/\"},\"wordCount\":277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/\",\"name\":\"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=\",\"datePublished\":\"2022-10-27T12:20:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/","og_locale":"en_US","og_type":"article","og_title":"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022 - Market Newsdesk","og_description":"NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Rain Therapeutics Inc. (NasdaqGS: RAIN), (\u201cRain\u201d), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company\u2019s business and financial results. Conference Call and Webcast Details: Date: November 10, 2022Time: 2:00 PT (5:00 pm ET)Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) \/ 1 (201) 389-0920 (International) Conference ID: &hellip; Continue reading \"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T12:20:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022","datePublished":"2022-10-27T12:20:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/"},"wordCount":277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/","name":"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=","datePublished":"2022-10-27T12:20:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2ODU3MiM1MjE0MTAyIzIyMDYxOTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rain-therapeutics-to-report-third-quarter-2022-financial-results-and-highlights-of-recent-progress-on-november-10-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701823","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701823"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701823\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701823"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701823"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701823"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}